



**UNIKLINIK  
KÖLN**

**Klinik und Poliklinik  
für Nuklearmedizin**

Uniklinik Köln | Klinik und Poliklinik für Nuklearmedizin  
Kerpener Straße 62 · 50937 Köln



**Prof. Dr. med. H. Schicha**  
Direktor

Anmeldung Sekretariat:  
Frau Starvaggi oder Frau Meyer  
Telefon: +49 221 478-4052  
Telefax: +49 221 478-6777  
nuklearmedizin@uk-koeln.de  
www.uk-koeln.de

Köln, den 1.2.2011

**Publikationen**  
**der Klinik und Poliklinik für Nuklearmedizin**  
**in nationalen und internationalen Journalen**  
**mit Peer-Review**  
**aus den Jahren 2000 – 2010**

**(Stand: 1. Februar 2011)**

Kerpener Straße 62  
50937 Köln  
Telefon: +49 221 478-0  
Telefax: +49 221 478-4095

[www.uk-koeln.de](http://www.uk-koeln.de)

**Universitätsklinikum Köln (AöR)**

Vorstand: Prof. Dr. Edgar Schömig (Vorsitzender und Ärztlicher Direktor) • Dipl.-Kfm. Günter Zwilling (Kaufmännischer Direktor)  
Prof. Dr. Joachim Klosterkötter (Dekan) • Kai-Uwe Buschina (komm. Pflegedirektor) • Prof. Dr. Peer Eysel (stellv. Ärztlicher Direktor)  
Bank für Sozialwirtschaft Köln • BLZ: 370 205 00 • Konto: 815 0000 • IBAN: DE04 3702 0500 0008 1500 00 • BIC: BFSWDE33XXX  
Steuernummer: 223/5911/1092 • Ust-IdNr.: DE 215 420 431 • IK: 260 530 283

ÖPNV: Straßenbahn Linie 9 Hst. Lindenburg, Linie 13 Hst. Gleueler Str./Gürtel • Bus Linie 146 Hst. Leibplatz

## Publikationen 2000

Baer FM, Theissen P, Crnac J, Schmidt M, Deutsch HJ, Sechtem U, Schicha H, Erdmann E. Head to head comparison of dobutamine-transoesophageal echocardiography and dobutamine-magnetic resonance imaging for the prediction of left ventricular functional recovery in patients with chronic coronary artery disease. *Eur Heart J* 2000; 21(12): 981-991.

Baer FM, Crnac J, Schmidt M, Jochims M, Theissen P, Schneider C, Schicha H, Erdmann E. Magnetic resonance pharmacological stress for detecting coronary disease. *Herz* 2000; 25(4): 400-8.

Börner AR, Voth E, Theissen P, Wienhard K, Wagner R, Schicha H. Glucose metabolism of the thyroid in autonomous goiter measured by F-18-FDG-PET. *Exp Clin Endocrinol Diabetes* 2000; 108: 191-196.

Büll U, Bartenstein P, Kirsch CM, Schicha H. [Combined systems for SPECT, Coincidence, PET and CT - Technical spectrum, operation requirements and possible applications]. *Nuklearmedizin* 2000; 39(1): 3A-6A.

Dietlein M, Moka D, Scheidhauer K, Schmidt M, Theissen P, Voth E, Eschner W, Schicha H. Follow-up care of differentiated thyroid cancer: Comparison of multiple diagnostic tests. *Nucl Med Commun* 2000; 21: 991-1000.

Dietlein M, Weber K, Gandjour A, Moka D, Theissen P, Lauterbach KW, Schicha H. Cost-effectiveness of FDG-PET for the management of solitary pulmonary nodules: a decision analysis based on cost reimbursement in Germany. *Eur J Nucl Med* 2000; 27 : 1441-1456.

Dietlein M, Weber K, Gandjour A, Moka D, Theissen P, Lauterbach KW, Schicha H. Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer (NSCLC): priority for a PET-based strategy after nodal-negative CT results. *Eur J Nucl Med* 2000; 27: 1598-1609.

Eschner W, Vogg R, Braunlich I, Mack C, Wagner R, Schicha H. Incorporation risks for workers in PET centers. *Radiat Prot Dosimetry* 2000; 89 (3-4): 211-213.

Hussy E, Voth E, Schicha H. [Sonographic determination of thyroid volume – comparison with surgical data]. *Nuklearmedizin* 2000; 39(4): 102-107.

Jungehülsing M, Scheidhauer K, Damm M, Pietrzyk U, Eckel H, Schicha H, Stennert E. 2[F]-fluoro-2-deoxy-D-glucose positron emission tomography is a sensitive tool for the detection of occult primary cancer (carcinoma of unknown primary syndrome) with head

and neck lymph node manifestation. *Otolaryngol Head Neck Surg* 2000 123(1): 294-301.

Kreuzberg U, Theissen P, Schicha H, Schröder F, Mehlhorn U, de Vivie ER, Boknik P, Neumann J, Grohe C, Herzig S. Single-channel activity and expression of atrial L-type Ca(2+) channels in patients with latent hyperthyroidism. *Am J Physiol Heart Circ Physiol* 2000; 278(3): 723-730.

Krug B, Dietlein M, Groth W, Stützer H, Psaras T, Gossmann A, Scheidhauer K, Schicha H, Lackner K. Fluor-18-fluorodeoxyglucose positron emission tomography (FDG-PET) in malignant melanoma. Diagnostic comparison with conventional imaging methods. *Acta Radiol* 2000; 41: 446-452.

Malja S, Schomäcker K, Malja E. Preparation of Y-90 by the Sr-90-Y-90 generator for medical purpose. *J Radioanal Nucl Chem* 2000; 245(2): 403-406.

Moka D, Voth E, Dietlein M, Larena-Avellaneda A, Schicha H. Preoperative localization of parathyroid adenomas using <sup>99m</sup>Tc-MIBI scintigraphy. *Am J Med* 2000; 108(9): 733-736.

Moka D, Voth E, Dietlein M, Larena-Avellaneda A, Schicha H. <sup>99m</sup>Tc-MIBI-SPECT in preoperative diagnostics of primary hyperparathyroidism. *Surgery* 2000; 128(1): 29-35.

Moka D, Eschner W, Voth E, Dietlein M, Larena-Avellaneda A, Schicha H. Iterative reconstruction: an improvement of technetium-99m MIBI SPET for the detection of parathyroid adenomas? *Eur J Nucl Med* 2000; 27(5): 485-489.

Raffelt K, Moka D, Süllentrop F, Dietlein M, Hahn J, Schicha H. Systemic alterations in phospholipid concentrations of blood plasma in patients with thyroid carcinoma: an in-vitro <sup>31</sup>P high resolution NMR study. *NMR Biomed* 2000; 13 : 8-13.

Schmidt M, Theissen P, Deutsch HJ. Double-outlet right ventricle after operative correction. *Clin Cardiol* 2000; 23(6): 459.

Schmidt M, Theissen P, Klempt G, Deutsch HJ, Baer FM, Dietlein M, Moka D, Erdmann E, Schicha H. Long-term follow-up of 82 patients with chronic disease of the thoracic aorta using spin-echo and cine gradient magnetic resonance imaging. *Magn Reson Imaging* 2000; 18(7): 795-806.

Schmidt M, Theissen P, Deutsch HJ, Dederichs B, Franzen D, Erdmann E, Schicha H. Congenitally corrected transposition of the great arteries (L-TGA) with situs inversus totalis in adulthood; findings with magnetic resonance imaging. *Magn Reson Imaging* 2000 18(4): 417-422.

Schmidt M, Scheidhauer K, Urbanek V, Luyken C, Friese M, Voth E, Schicha H. [Metastasizing follicular thyroid carcinoma with intracranial iodine-131 uptake in brain edema due to a frontal meningioma]. *Nuklearmedizin* 2000; 39(1): 38-39.

Schneider CA, Voth E, Moka D, Wagner R, Schicha H, Erdmann E, Baer FM. [Dobutamine-induced changes in the myocardial blood flow in patients with coronary heart diseases. A quantitative analysis using [<sup>15</sup>O] H<sub>2</sub>O positron emission tomography]. *Dtsch Med Wochenschr* 2000; 125(17): 512-516.

Schomäcker K, Schicha H. Use of myocardial imaging agents for tumour diagnosis-a success story ? *Eur J Nucl Med* 2000; 27: 1845-1863.

Schwenk A, Eschner W, Kremer G, Ward LC. Assessment of intracellular water by whole body bioelectrical impedance and total body potassium in HIV-positive patients. *Clin Nutr* 2000; 19(2): 109-113.

Sechtem U, Theissen P, Baer FM. [Magnetic resonance tomography in clinical cardiology]. *Z Kardiol* 2000; 89(Suppl 1): 67-73.

Smolarz K, Malke G, Voth E, Scheidhauer K, Eckel HE, Jungehülsing M, Schicha H. Hypothyroidism after therapy for larynx and pharynx carcinoma. *Thyroid* 2000; 10(5): 425-429.

Tate AR, Foxall PJ, Holmes E, Moka D, Spraul M, Nicholson JK, Lindon JC. Distinction between normal and renal cell carcinoma kidney cortical biopsy samples using pattern recognition of (1)H magic angle spinning (MAS) NMR spectra. *NMR Biomed* 2000; 13(2): 64-71.

Urbanek V, Schmidt M, Moka D, Hillger HW, Voth E, Wellner U, Schicha H. [Effect of iodine application during radioiodine therapy in patients with impending therapy failure]. *Nuklearmedizin* 2000; 39(4): 108-112.

## Publikationen 2001

Diehl M, Risse JH, Brandt-Mainz K, Dietlein M, Bohuslavizki KH, Matheja P, Lange H, Bredow J, Körber C, Grünwald F. Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study. *Eur J Nucl Med* 2001; 28: 1671–1676.

Dietlein M, Moka D, Weber K, Theissen P, Schicha H. Cost-effectiveness of PET for the management of lung tumours: comparison of economic data. *Nuklearmedizin* 2001; 40: 122–128.

Ebel H, Schomäcker K, Balogh A, Volz M, Funke J, Schicha H, Klug N. High cervical spinal cord stimulation (CSCS) increases regional cerebral blood flow after induced subarachnoid hemorrhage in rats. *Minim Invasive Neurosurg* 2001; 44(3): 167-171.

Ebel H, Semmelmann G, Friese M, Volz M, Lee JY, Dück M, Schomäcker K, Varga J, Furka I, Schröder R, Klug N. Effects of electrical stimulation of the Gasserian ganglion on regional cerebral blood flow after induced subarachnoid hemorrhage in pigs evaluated by  $^{99m}\text{Tc}$ -HMPAO-SPECT. *Minim Invasive Neurosurg* 2001; 44(1): 50-57.

Füssl R, Baer FM, Schwinger RH, La Rosee K, Diederichs H, Dederichs B, Höpp HW. [Angiographically unexplained myocardial ischemia in high grade coronary stenosis with main stem involvement in intravascular ultrasound.] *Dtsch Med Wochenschr* 2001; 126(10): 286-272.

Georger B, Hero B, Harms D, Grebe J, Scheidhauer K, Berthold F. Metabolic activity and clinical features of primary ganglioneuromas. *Cancer* 2001; 91(10): 1905-1913.

Kim WY, Danias PG, Stuber M, Flamm SD, Plein S, Nagel E, Langerak SE, Weber OM, Pedersen EM, Schmidt M, Botnar RM, Manning WJ. Coronary magnetic resonance angiography for the detection of coronary stenosis. *N Engl J Med* 2001; 345(26): 1863-1869.

Moka D, Baer FM, Theissen P, Schneider CA, Dietlein M, Erdmann E, Schicha H. Non-Q-wave myocardial infarction: impaired myocardial energy metabolism in regions with reduced  $^{99m}\text{Tc}$ -MIBI accumulation. *Eur J Nucl Med* 2001; 28: 602-607.

Rosenkranz S, Voth E, LaRosée K, Baer FM, Kettering K, Smolarz K, Moka D, Schicha H, Erdmann E, Deutsch H. Identification of hemodynamically significant restenosis after percutaneous transluminal coronary angioplasty in acute myocardial infarction by transesophageal dobutamine stress echocardiography and comparison with myocardial Single Photon Emission Computed Tomography. *J Interven Cardiol* 2001; 14: 271–282.

Schmidt M, Theissen P, Moka D, Voth E, Schmitter HT, Schicha H. Tc-99m MIBI SPECT correlated with magnetic resonance imaging for cardiac evaluation of a patient with congenitally corrected transposition of the great arteries (L-TGA). Clin Nucl Med 2001; 26(8): 714-5.

Schmidt M, Jochims M, Theissen P, Baer FM, Crnac J, Voth E, Schneider CA, Erdmann E, Schicha H. [Comparison of dobutamine-stress magnetic resonance imaging and dipyridamole-Tl-201-SPECT as alternative strategies for the detection of coronary artery disease in patients not suitable for stress echocardiography]. Nuklearmedizin 2001; 40(6): 198-206.

Schomäcker K, Fischer T, Eschner W, Gaidouk MI, Schicha H: [Exhalation of  $^{131}\text{I}$  after radioiodine therapy: time dependence and chemical form]. Nuklearmedizin 2001; 40: 15-22.

Simon T, Voth E, Berthold F. Asymmetric salivary gland  $^{123}\text{I}$ -meta-iodobenzylguanidine uptake in a patient with cervical neuroblastoma and Horner syndrome. Med Pediatr Oncol 2001; 36(4): 489-490.

Urbanek V, Voth E, Moka D, Schicha H. [Radioiodine therapy of Graves' disease--a dosimetric comparison of various therapy regimens of antithyroid agents]. Nuklearmedizin 2001; 40(4): 111-115.

Weber K, Wellner U, Voth E, Schicha H. [Influence of stable iodine on the uptake of the thyroid – model versus experiment.] Nuklearmedizin 2001; 40(1): 31-37.

Weihrauch MR, Re D, Scheidhauer K, Ansen S, Dietlein M, Bischoff S, Bohlen H, Wolf J, Schicha H, Diehl V, Tesch H. Thoracic positron emission tomography using  $^{18}\text{F}$ -fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 2001; 98: 2930–2934.

## Publikationen 2002

Bäumer AT, Nickenig G, Moka D, Bohm M: [Coronary-subclavian steal syndrome]. Dtsch Med Wochenschr 2002; 127(21): 1134-6.

Becker W, Schicha H. The thyroid. Eur J Nucl Med Mol Imaging 2002; 29(Suppl 2): S401-S403.

Damm M, Vent J, Schmidt M, Theissen P, Eckel HE, Lötsch J, Hummel T: Intranasal volume and olfactory function. Chemical Senses 2002; 27: 831 – 839.

Dietlein M, Schicha H. PET in der nuklearmedizinischen Diagnostik – Kosten/Nutzen-Aspekte. Nuklearmedizin 2002; 41: 202-207.

Dose J, Kotzerke J, Schicha H, Rieber A, Schelling M, Paulsen F, Avril N. Recommendations of the 3<sup>rd</sup> interdisciplinary German consensus conference PET in oncology III. Geburtshilfe Frauenheilkd 2002; 62(7): 644-651.

Herholz K, Schopphoff H, Schmidt M, Mielke R, Eschner W, Scheidhauer K, Schicha H, Heiss WD, Ebmeier K. Direct comparison of spatially normalized PET and SPECT scans in Alzheimer's disease. J Nucl Med 2002; 43(1): 21-26.

Kahaly GJ, Dietlein M. Cost estimation of thyroid disorders in Germany. Thyroid 2002; 12: 909-914.

Kreuzberg U, Schmidt M, Metzger R, Schirmacher P, Kämmerer F, Schütt-Gerowitt H, Schicha H: Zervikale Tuberkulose einer Ductus-thyreoglossus-Zyste. Nuklearmedizin 2002; 41: 87–89.

Leyendeckers H, Voth E, Schicha H, Hunzelmann N, Banga P, Schmitz J. Frequent detection of thyroid peroxidase-specific IgG+ memory B cells in blood of patients with autoimmune thyroid disease. Eur J Immunol 2002; 32(11): 3126-3132.

Moka D, Dietlein M, Schicha H: Radioiodine therapy and thyrostatic drugs and iodine. Eur J Nucl Med Mol Imaging 2002; 29(Suppl 2): S486-S491.

Moka D, Dietlein M, Raffelt K, Hahn J, Schicha H. Differentiation between healthy thyroid remnants and tumor tissue after radioiodine therapy in patients with differentiated thyroid carcinoma using in-vitro phosphorus-31 magnetic resonance spectroscopy. Am J Med 2002; 112(8): 634-641.

Schaefer WM, Moka D, Brockmann HA, Schomaecker K, Schicha H: 201TI, 99mTc-MIBI, 99mTc-tetrofosmin and 99mTc-furifosmin: relative retention and clearance kinetics in retrogradely perfused guinea pig hearts. Nucl Med Biol 2002; 29(2): 243-54.

Scheidhauer K, Odatzidu L, Kiencke P, Schicha H. [Body weight gain after radioiodine therapy in hyperthyroidism]. Nuklearmedizin 2002; 41(1): 47-51.

Schicha H, Dietlein M. Morbus Basedow und Autonomie – Radioiodtherapie. Nuklearmedizin 2002; 41: 63-70.

Schmidt M, Fischer E, Dietlein M, Michel O, Weber K, Moka D, Stennert E, Schicha H. Clinical value of somatostatin receptor imaging in patients with suspected head and neck paragangliomas. Eur J Nucl Med Mol Imaging 2002; 29(12): 1571-1580.

Schmidt M, Jockenhövel F, Theissen P, Dietlein M, Krone W, Schicha H. [Assessment of endocrine disorders of the hypothalamic-pituitary axis by nuclear medicine techniques]. Nuklearmedizin 2002; 41(4): 80-90.

Süllentrop F, Moka D, Neubauer S, Haupt G, Engelmann U, Hahn J, Schicha H. 31P NMR spectroscopy of blood plasma: determination and quantification of phospholipid classes in patients with renal cell carcinoma. NMR Biomed 2002; 15(1): 60-8.

Weihrauch MR, Re D, Bischoff S, Scheidhauer K, Dietlein M, Ansen S, Franklin J, Bohlen H, Wolf J, Schicha H, Diehl V, Tesch H. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease. Ann Hematology 2002; 81: 20-25.

## Publikationen 2003

Diedrichs H, Weber M, Voth E, Koulousakis A, Zobel C, Schwinger RH. [Increased myocardial blood flow after spinal cord stimulation in patients with refractory angina pectoris]. Med Klin (Munich) 2003; 98(3): 146-150.

Dietlein M, Dressler J, Eschner W, Lassmann M, Leisner B, Reiners C, Schicha H. Verfahrensanweisung zum Radioiodtest (Version 2). Nuklearmedizin 2003; 42 : 116-119.

Dietlein M, Dressler J, Eschner W, Leisner B, Reiners C, Schicha H. Verfahrensanweisung für die Schilddrüsenszintigraphie (Version 2). Nuklearmedizin 2003; 42 : 120-122.

Dietlein M, Dressler J, Eschner W, Leisner B, Reiners C, Schicha H. Verfahrensanweisung für die Iod-131-Ganzkörperszintigraphie beim differenzierten Schilddrüsenkarzinom (Version 2). Nuklearmedizin 2003; 42 : 123-125.

Dietlein M, Dressler J, Grünwald F, Joseph K, Leisner B, Moser E, Reiners C, Rendl J, Schicha H, Schober O. Leitlinien zur Schilddrüsendiagnostik (Version 2) Nuklearmedizin 2003; 42: 109-115.

Dietlein M, Moka D, Schmidt M, Theissen P, Schicha H: Prävention, Screening und Therapie gutartiger Schilddrüsenenerkrankungen unter dem Aspekt von Kosten und Nutzen. Nuklearmedizin 2003; 42: 181-189.

Dietlein M, Schicha H. Lifetime follow-up care is necessary for all patients with treated thyroid nodules [letter]. Eur J Endocrinol 2003; 148: 377-379.

Dietlein M, Schicha H. Vergütung der PET in der Onkologie in Europa: Eine Umfrage. Nuklearmedizin 2003; 42: 80-85.

Dietlein M, Weber W, Schwaiger M, Schicha H. <sup>18</sup>F-Fluorodeoxyglukose-Positronenemissionstomographie in der Rezidivdiagnostik des kolorektalen Karzinoms: evidenzbasierte Empfehlungen und Kosten/Nutzenabwägungen. Nuklearmedizin 2003; 42: 145-156.

Hummel T, Damm M, Vent J, Schmidt M, Theissen P, Larsson M, Klussmann JP: Depth of olfactory sulcus and olfactory function. Brain Research 2003; 975: 85–89.

Kappert K, LaRosée K, Karasch T, Kuhn-Regnier F, Schmidt M, Rosenkranz S: Dünnwandiges Herzspitzenaneurysma bei hypertropher obstruktiver Kardiomyopathie. Dtsch Med Wochenschr 2003; 128: 1342–1346.

Staak JO, Dietlein M, Engert A, Weihrauch MR, Schomäcker K, Fischer T, Eschner W, Borchmann P, Diehl V, Schicha H, Schnell R. Hodgkin's lymphoma in nuclear medicine: diagnostic and therapeutic aspects. Nuklearmedizin 2003; 42: 19-24.

Walter C, Scheidhauer K, Scharl A, Göring UJ, Theissen P, Kugel H, Krahe T, Pietrzyk U. Clinical and diagnostic value of preoperative MR mammography and FDG-PET in suspicious breast lesions. Eur Radiol 2003; 13(7): 1651-1656.

Weber W, Dietlein M, Hellwig D, Kirsch C-M, Schicha H, Schwaiger M. PET mit <sup>18</sup>F-Fluorodeoxyglukose in der Diagnostik des nicht-kleinzelligen Bronchialkarzinoms: evidenzbasierte Empfehlungen und Kosten/Nutzenabwägungen. Nuklearmedizin 2003; 42: 135-144.

Weihrauch MR, Dietlein M, Schicha H, Diehl V, Tesch H. Prognostic significance of <sup>18</sup>F-fluorodeoxyglucose positron emission tomography in lymphoma. Leuk Lymphoma 2003; 44: 15-22.

## Publikationen 2004

Breustedt B, Paetz H, Schicha H, Eschner W. [Calibration of a whole body counter using Monte Carlo methods.] *Z Med Phys* 2004; 14(2): 85-94.

Dietlein M, Dressler J, Farahati J, Grünwald F, Leisner B, Moser E, Reiners C, Schicha H, Schober O. Verfahrensanweisung zur Radioiodtherapie (RIT) beim differenzierten Schilddrüsenkarzinom (Version 2). *Nuklearmedizin* 2004; 43: 115-120.

Dietlein M, Dressler J, Grünwald F, Leisner B, Moser E, Reiners C, Schicha H, Schneider P, Schober O. Leitlinie zur Radioiodtherapie bei benignen Schilddrüsenerkrankungen (Version 3). *Nuklearmedizin* 2004; 43: 217-220.

Dietlein M, Schober O, Schicha H. Über- oder Untertherapie des papillären Mikrokarzinoms der Schilddrüse? Überlegungen zur ablativen Radioiodtherapie. *Nuklearmedizin* 2004; 43: 107-114.

Fischer T, Schomäcker K, Schicha H. Labelling, purification, and receptor affinity of radioactive iododiethylstilbestrol (I-DES) with high specific activity and first structure analysis with <sup>nat</sup>I-DES. *J Label Comp Radiopharm* 2004; 47: 669-678.

Reiners C., Wegscheider K., Schicha H., Theissen P., Vaupel R., Wrbitzky R., Schumm-Draeger PM. Prevalence of thyroid disorders in the working population of Germany: ultrasonography screening in 96,278 unselected employees, *Thyroid* 2004; 14(11): 926-932.

Schicha H, Reiners C, Moser E, Schober O. Subclinical thyroid disease. *Nuklearmedizin* 2004; 43: 69-71.

Schmidt M, Schmalenbach M, Jungehülsing M, Theissen P, Dietlein M, Schröder U, Eschner W, Stennert E, Schicha H. <sup>18</sup>F-FDG PET for detecting recurrent head and neck cancer, local lymph node involvement and distant metastases. Comparison of qualitative visual and semiquantitative analysis. *Nuklearmedizin* 2004; 43: 91–101.

Schmidt M, Voth E, Schneider CA, Theissen P, Wagner R, Baer FM, Schicha H. F-18-FDG uptake is a reliable predictor of functional recovery of akinetic but viable infarct regions as defined by magnetic resonance imaging before and after revascularization. *Magn Reson Imaging* 2004; 22: 229 – 236.

## Publikationen 2005

Albus C, Theissen P, Hellmich M, Griebenow R, Wilhelm B, Aslim D, Schicha H, Köhle K. Long-term effects of ambulant, multimodal intervention on myocardial perfusion and cardiac occurrence in patients with coronary cardiaccdisease – a randomised controlled study. *Psychother Psychosom Med Psychol* 2005; 55(2): 91.

Biermann M, Pixberg MK, Dörr U, Dietlein M, Schlemmer H, Grimm J, Zajic T, Nestle U, Ladner S, Sepehr-Rezai S, Rosenbaum S, Puskás C, Fostitsch P, Heinecke A, Schuck A, Willich N, Schmid KW, Dralle H, Schober O. Impact of clinical practice guidelines on radioiodine therapy for differentiated thyroid carcinoma. *Nuklearmedizin* 2005; 44: 229-237.

Diedrichs H, Zobel C, Theissen P, Weber M, Koulousakis A, Schicha H, Schwinger RH. Systematic relief precedes improvement of myocardial blood flow in patients under spinal cord stimulation. *Curr Control Trials Cardiovasc Med* 2005; 6(1):7.

Dietlein M, Schicha H. Amiodarone-induced thyrotoxicosis due to destructive thyroiditis. Therapeutic considerations. *Exp Clin Endocrinol Diabetes* 2005; 113: 145-151.

Dietlein M, Luyken WA, Schicha H, Larena-Avellaneda A. Incidental multifocal papillary microcarcinomas of the thyroid: Is subtotal thyroidectomy combined with radioiodine ablation enough? *Nucl Med Commun* 2005; 26: 3-8.

Dietlein M, Pels H, Schulz H, Borchmann P, Schomäcker K, Fischer T, Eschner W, Schicha H, Engert A, Schnell R. Imaging of CNS lymphomas with iodine-123 labeled rituximab. *Eur J Haematol* 2005; 74: 348-352.

Dietlein M, Kobe C, Schmidt M, Schicha H. Das Inzidentalom der Schilddrüse. Über- oder Unterdiagnostik eines epidemiologischen Befundes? *Nuklearmedizin* 2005; 44: 213-224.

Grönke S, Schmidt M, Schwinger RHG. Typische Angina-pectoris-Beschwerden ohne koronare Makroangiopathie. *Dtsch Med Wochenschr* 2005, 130: 942-945.

Kersting UG, Stubendorff JJ, Schmidt MC, Brüggemann G-P. Changes in knee cartilage volume and serum COMP concentration after running exercise. *OsteoArthritis and Cartilage* 2005; 13: 925-934.

Luster M, Felbinger R, Dietlein M, Reiners C. Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a 130-patient pilot survey on consequences of

hypothyroidism and pharmacoeconomic comparison with recombinant thyrotropin administration. *Thyroid* 2005; 15: 1147-1155.

Schmidt M, Eschner W, Dietlein M, Theissen P, Schicha H. Konventionelle nuklearmedizinische Tumordiagnostik (Tumor-SPECT): Was ist angesichts von <sup>18</sup>F-FDG-PET noch aktuell? *Nuklearmedizin* 2005; 44: 37-48.

Schnell R\*, Dietlein M\*, Staak JO, Borchmann P, Schomäcker K, Fischer T, Eschner W, Hansen H, Morschhauser F, Schicha H, Diehl V, Raubitschek A, Engert A. Treatment of refractory Hodgkin lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody (<sup>131</sup>I-Ki-4). *J Clin Oncol* 2005; 23: 4669-4678. [\*Both authors contributed equally to this work.]

Schomäcker K, Dietlein M, Schnell R, Pinkert J, Eschner W, Zimmermanns B, Fischer T, Engert A, Schicha H. Radioimmuntherapie mit <sup>90</sup>Y-markiertem Ibritumomab-Tiuxetan: Klinik, Radiopharmazie, Strahlenschutz, Perspektiven. *Nuklearmedizin* 2005; 44: 166-177.

Schomäcker K, Dietlein M, Mödder G, Boddenberg-Pätzold B, Zimmermanns B, Fischer T, Schicha H. Stability of radioactive colloids for radiation synovectomy: influence of x-ray contrast agents, anesthetics and glucocorticoids in vitro. *Nucl Med Commun* 2005; 26: 1027-1035.

Theissen P, Schneider PM, Dietlein M, Hölscher AH, Schicha H. Wertigkeit der Positronenemissionstomographie für das Staging beim Ösophaguskarzinom. *Viszeralchirurgie* 2005; 40: 242-245.

Theissen P, Schneider PM, Baldus SE, Jost A, Dietlein M, Müller RP, Hölscher AH, Schicha H. Monitoring of tumor response to neoadjuvant radio-chemotherapy of esophageal carcinoma by F-18-FDG-PET. *Chinese German J Clin Oncol* 2004; 3: 257-262.

## Publikationen 2006

Dederichs B, Dietlein M, Jenniches-Kloth B, Schmidt M, Theissen P, Schicha H. Radioiodine therapy of Graves' hyperthyroidism in patients without pre-existing ophthalmopathy: can glucocorticoids prevent the development of new ophthalmopathy? *Exp Clin Endocrinol Diabetes* 2006; 366-370.

Delank KS, Schmidt M, Michael JWP, Dietlein M, Schicha H, Eysel P. The implications of  $^{18}\text{F}$ -FDG-PET for the diagnosis of endoprosthetic loosening and infection in hip and knee arthroplasty. *BMC Musculoskeletal Disorders* 2006; 7: 20 – 29.

Dietlein M, Dederichs B, Kobe C, Theissen P, Schmidt M, Schicha H. Therapiekonzepte der euthyreoten Struma nodosa – Die Radioiodtherapie bietet eine attraktive Alternative zur Operation. *Nuklearmedizin* 2006; 45(1): 21-34.

Guntinas-Lichius O, Klusmann JP, Dinh S, Dinh M, Schmidt M, Semrau R, Mueller RP. Diagnostic work-up and outcome of cervical metastases from an unknown primary. *Acta Oto-Laryngol* 2006; 126: 536–544.

Marx K, Moka D, Schomäcker K, Fischer T, Dietlein M, Gabruck-Szostak B, Schicha H. Cell death induced by radioiodine therapy in differentiated thyroid carcinoma: Necrosis or apoptosis? *Nucl Med Commun* 2006; 27: 353-358.

Mernagh P, Campell S, Dietlein M, Luster M, Mazzaferri E, Weston AR. Cost-effectiveness of using recombinant human TSH (rhTSH) prior to radioiodine therapy ablation for thyroid cancer, compared with treating patients in a hypothyroid state: the German perspective. *Eur J Endocrinol* 2006; 155: 405-414.

Mix M, Eschner W. Bildrekonstruktion und Quantifizierung in der Emissionstomographie. *Z Med Phys* 2006; 16(1): 19-30.

Otto C, Jensen M, Dietlein M, Fischer T, Zimmermanns B, Schmidt M, Tawadros S, Börner SM, Weber SA, Spitz R, Berthold F, Schicha H, Schomäcker K. Localization of  $^{131}\text{I}$ -labeled monoclonal antibody ERIC1 in a subcutaneous xenograft model of neuroblastoma in SCID mice. *Nucl Med Commun* 2006; 27: 171-178.

Schmidt M, Simon T, Hero B, Eschner W, Dietlein M, Sudbrock F, Bongartz R, Berthold F, Schicha H. Is there a benefit of  $^{131}\text{I}$ -MIBG therapy in the treatment of children with stage 4 neuroblastoma. *Nuklearmedizin* 2006; 45: 145-151.

Schmidt M, Schneider C, Theissen P, Erdmann E, Schicha H. QT dispersion in comparison to TI-201-SPECT for detection of myocardial ischaemia. *Int J Cardiol* 2006; 113: 327-331.

Schmidt M, Gorbauch E, Dietlein M, Faust M, Stützer H, Eschner W, Theissen P, Schicha H. Incidence of post-radioiodine immunogenic hyperthyroidism / Graves' disease in relation to a temporary increase in TSH-receptor antibodies after radioiodine therapy for autonomous thyroid disease. *Thyroid* 2006; 16(3): 281-288.

Schmidt M, Dietlein M, Schröder U, Schicha H. False-positive uptake of I-131 in a laryngocele mimicking thyroid remnant after thyroidectomy for papillary thyroid carcinoma. *Clin Nucl Med* 2006; 31: 716-717.

Simon T, Hero B, Bongartz R, Schmidt M, Müller RP, Berthold F. Intensified external-beam radiation therapy improves the outcome of stage 4 neuroblastoma in children > 1 year with residual disease. *Strahlenther Onkol* 2006; 182: 389-394.

Sudbrock F, Eschner W, Schmidt M, Schicha H, Simon T, Hero B. Dosimetrie bei der Therapie von Neuroblastomen mit 131I-mIBG. *Nuklearmedizin* 2006; 40: 254-261.

Tossios P, Müller-Ehmsen J, Schmidt M, Scheid C, Ünal N, Moka D, Schwinger RHG, Mehlhorn U. No evidence of myocardial restoration following transplantation of mononuclear bone marrow cells in coronary bypass grafting surgery patients based upon cardiac SPECT and <sup>18</sup>F-PET. *BMC Medical Imaging* 2006; 6: 7 (published online).

Bamberg M, Diehl V, Herrmann T, Juergens H, Siewert JR, Bartenstein P, Baum RP, Dietlein M, Geworski L, Haberkorn U, Kluge R, Knapp WH, Kotzerke J, Kuwert T, Nitzsche E, Reske SN, Reuland P, Schicha H, Schober O, Schwaiger M, Stabell U, van den Hoff J. Positron emission tomography (PET) in oncology: a part of medical therapeutic expertise. *Dtsch Med Wochenschr* 2006; 131 (10): 512-515.

Schleimer K, Stippel DL, Kaspar HU, Tawadros S, Suer C, Schomäcker K, Hölscher A, Beckurts KT. Auxiliary liver transplantation with flow-regulated portal vein arterialisation offers a successful therapeutic option in acute hepatic failure – investigations in heterotopic auxiliary rat liver transplantation. *Transpl Int* 2006; 19(7): 581-588.

Tossios P, Müller-Ehmsen J, Schmidt M, Scheid C, Ünaf N, Moka D, Schwinger RHG, Mehlhorn U. No evidence of myocardial restoration following transplantation of mononuclear bone marrow cells in coronary bypass grafting surgery patients based upon cardiac SPECT and <sup>18</sup>F-PET. *Heart Views* 2006; 7(3): 88-96.

## Publikationen 2007

Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, Wiseman GA, Kostakoglu L, Scheidhauer K, Buck A, Naumann R, Spaepen K, Hicks RJ, Weber WA, Reske SN, Schwaiger M, Schwartz LH, Zijlstra JM, Siegel BA, Cheson BD. Use of Positron Emission Tomography (PET) for Response Assessment of Lymphoma: Consensus Recommendations of the Imaging Subcommittee of the International Harmonization Project (IHP) in Lymphoma. *J Clin Oncol* 2007; 25(2): 571-578.

Dietlein M, Moka D, Reinholz U, Schmidt M, Schomäcker K, Schicha H, Wellner U. Who might benefit from administration of additional inactive iodine during radioiodine therapy for Graves' disease ? *Nuklearmedizin* 2007, 41 (3): 77-87.

Dietlein M, Wegscheider K, Vaupel R, Schmidt MC, Schicha H. Management of multinodular goiter in Germany. Do the approaches of thyroid specialists and primary care practitioners differ? (*Papillon* 2005) *Nuklearmedizin* 2007; 41 (3): 65-75.

Dietlein M, Wegscheider K, Vaupel R, Schmidt MC. Ärztebefragung zur Versorgung bei diffuser Struma: Kombinationstherapie hat die Nase vorn. *Der Hausarzt* 2007; Heft 7: 50-57.

Schmidt M, Delank K-S, Dietlein M, Schicha H. Nuklearmedizinische Abklärung bei vermuteter Infektion einer Hüft- oder Knie-TEP. *Der Nuklearmediziner* 2007; 30: 140-153.

Kahaly G, Dietlein M, Gärtner R, Mann K, Dralle H. Amiodaron und Schilddrüsendysfunktion. *Dtsch Ärzteblatt* 2007; 104(51-52): C 3021 – C 3026.

Dietlein M, Dressler J, Escher W, Grünwald F, Lassmann M, Leisner B, Luster M, Moser E, Reiners C, Schicha H, Schober O. Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 3). [German]. *Nuklearmedizin* 2007; 46: 213-219.

Dietlein M, Dressler J, Eschner W, Grünwald F, Lassmann M, Leisner B, Luster M, Reiners C, Schicha H, Schober O. Procedure guideline for iodine-131 whole-body scintigraphy for differentiated thyroid cancer (version 3). *Nuklearmedizin* 2007; 46: 206-212.

Dietlein M, Dressler J, Grünwald F, Leisner B, Moser E, Reiners C, Schicha H, Schneider P, Schober O. Guideline for radioiodine therapy for benign thyroid diseases (version 4). [German] *Nuklearmedizin* 2007; 46: 220-223.

Dietlein M, Dressler J, Eschner W, Leisner B, Reiners C, Schicha H. Procedure guideline for thyroid scintigraphy (version 3). [German] Nuklearmedizin 2007; 46: 203-205.

Dietlein M, Dressler J, Eschner W, Lassmann M, Leisner B, Reiners C, Schicha H. Procedure guideline for radioiodine test (version 3). [German] Nuklearmedizin 2007; 46: 198-202.

Franzius C, Dietlein M, Biermann M, Frühwald M, Linden T, Bucsky P, Reiners C, Schober O. Procedure guideline for radioiodine therapy and <sup>131</sup>Iodine whole-body scintigraphy in paediatric patients with differentiated thyroid cancer. [German] Nuklearmedizin 2007; 46: 224-231.

Dietlein M, Schober O, Schicha H. Radioiodtherapie und <sup>131</sup>I-Ganzkörperszintigraphie zwischen evidentia und evidence. Anmerkungen zur Aktualisierung der Verfahrensanweisungen und Leitlinien. Nuklearmedizin 2007; 46: 155-160.

Jensen M, Klehr M, Vogel A, Schmitz S, Tawadros S, Mühlenhoff M, Plück A, Fischer T, Schomäcker K, Schultze JL, Berthold F. One step generation of fully chimeric antibodies using Cgamma1- and Ckappa transgenic mice. J Immunother 2007; 30: 338-349.

Kobe C, Schmidt M, Kracht L, Dietlein M, Schicha H. PET in der Onkologie: Nutzen und Chancen. best practice onkologie 2007; 2(3): 22-32.

Bachmann J, Ernestus K, Werner T, Garnier Y, Mallmann P, Pietsch C, Schicha H, Schmidt M. Detection of primary choriocarcinoma in the mediastinum by F-18 FDG positron emission tomography. Clin Nucl Med 2007; 32: 663-665.

Eschner W. Strahlenschutz bei der nuklearmedizinischen Bildgebung. Strahlenschutzpraxis 2007; 13(4): 16-21.

## Publikationen 2008

Wüllner U, Gündisch D, Herzog H, Minnerop M, Joe A, Warnecke M, Jessen F, Schütz C, Reinhardt M, Eschner W, Klockgether T, Schmaljohann J. Smoking upregulates alpha4beta2 nicotinic acetylcholine receptors in the human brain. *Neurosci Lett / Neuroscience Letter* 2008 ; 430 : 34-37.

Dietlein M, Wegscheider K, Vaupel R, Schmidt MC, Schicha H. Survey of management of solitary thyroid nodules in Germany. *Nuklearmedizin* 2008; 47: 87-96.

Dietlein M, Wieler H, Schmidt M, Schwab R, Goretzki PE, Schicha H. Routine measurement of serum calcitonin in patients with nodular thyroid disorders? [German]. *Nuklearmedizin* 2008; 47: 65-72.

Schmidt M, Thoma N, Dietlein M, Moka D, Eschner W, Faust M, Pollock M, Schröder W, von Hülst-Schlabrendorff M, Ehse W, Schicha H. <sup>99m</sup>Tc-MIBI SPECT in primary hyperparathyroidism. Influence of concomitant vitamin D deficiency for visualization of parathyroid. *Nuklearmedizin* 2008; 47: 1 - 7.

Kobe C, Eschner W, Sudbrock F, Weber I, Marx K, Dietlein M, Schicha H. Graves' disease and radioiodine therapy: is success of ablation dependent on the absorbed dose above 200 Gy? *Nuklearmedizin* 2008; 47: 13 - 17.

Kobe C, Weber I, Eschner W, Sudbrock F, Schmidt M, Dietlein M, Schicha H. Graves' disease and radioiodine therapy: is success of ablation dependent on the choice of thyreostatic medication? *Nuklearmedizin* 2008; 47: 153 - 166.

Schnell R, Dietlein M, Schomäcker K, Kobe C, Borchmann P, Schicha H, Hallek M, Engert A. Yttrium-90 ibritumimab tiuxetan induced complete remission in a patient with classical lymphocyte-rich Hodgkin lymphoma. *Onkologie* 2008; 31: 49-51.

Dietlein M, Bell E, Gemmer P, Göller T, Goretzki PE, Jacob R, Keuser R, Musholt TJ, Daid S, Schicha H, Schwab R, Wilbert H, Wieler H. Calcitonin-Screening bei der Knotenstruma? *Ärzteblatt Rheinland-Pfalz* 2008; Ausgabe 3/März 2008.

Kobe C, Dietlein M, Franklin J, Markova J, Lohri A, Amthauer H, Klutmann S, Knapp W, Zijlstra JM, Bockisch A, Weckesser M, Lorenz R, Schreckenberger M, Bares R, Eich HT, Mueller RP, Fuchs M, Borchmann P, Gossmann A, Schicha H, Diehl V, Engert A. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first line chemotherapy in advanced-stage Hodgkin Lymphoma. *Blood* 2008; 112: 3989-3994.

Sobottke R, Seifert H, Fätkenheuer G, Schmidt M, Goßmann A, Eysel P. Aktuelle Diagnostik und Therapie der Spondylodiszitis. Dtsch Arztebl 2008; 105(10): 181-187.

Schmidt M, Simon T, Hero B, Schicha H, Berthold F: The prognostic impact of functional imaging with 123I-mIBG in patients with stage 4 neuroblastoma > 1 year of age on a high-risk treatment protocol. Results of the German Neuroblastoma trial NB97. Eur J Cancer 2008; 44: 1552-1558.

Pfister R, Diedrichs H, Dietlein M, Erdmann E, Schneider CA. Typical and atypical takotsubo-like cardiomyopathy as a manifestation of pheochromocytoma. [letter] J Endocrinol Invest 2008; 31: 382-383.

Franzius C, Schmidt M, Hero B, Pfluger T, Hahn K. Procedure guidelines for MIBG-scintigraphy in children. Nuklearmedizin 2008; 47: 132-138.

Dietlein M, Kahaly G, Kobe C, Schmidt M, Derwahl K-M, Schicha H. Adipositas, Stoffwechsel und Schilddrüse: Ist der grenzwertig hohe TSH-Spiegel Ursache oder Sekundärphänomen der Adipositas? Nuklearmedizin 2008; 47: 181-187.

Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen W, Tennvall J, Bombardieri E. Guidelines for radioiodine treatment of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2008; 35: 1941-1959.

Schmidt M, Voell M, Rahlff I, Dietlein M, Kobe C, Faust M, Schicha H. Long-term follow-up of antithyroid peroxidase antibodies in patients with chronic autoimmune thyroiditis (Hashimoto's thyroiditis) treated with levothyroxine. Thyroid 2008; 18: 755-760.

Tossios P, Krausgrill B, Schmidt M, Fischer T, Halbach M, Fries JWU, Fahnenstich S, Frommolt P, Heppelmann I, Schmidt A, Schomäcker K, Fischer JH, Bloch W, Mehlhorn U., Schwinger RHG, Müller-Ehmsen J. Role of balloon occlusion for mononuclear bone marrow cell deposition after intracoronary injection in pigs with reperfused myocardial infarction. Eur Heart J 2008; 29: 1911-1921.

Schröder U, Dietlein M, Wittekindt C, Ortmann M, Stuetzer H, Vent J, Jungehuelsing M, Krug B. Is there a need for PET imaging to stage the N0 neck in T1-T2 squamous cell carcinoma of the oral cavity and oropharynx? Annals Otology Rhinology Laryngology 2008; 117(11): 854-863.

Reiners C, Dietlein M, Luster M. Radioiodine therapy in differentiated thyroid cancer: indications and procedures. Best Practice & Research Clinical Endocrinology & Metabolism 2008; 22(6): 989 - 1007

Kobe C, Dietlein M, Mauz-Körholz C, Engert A, Borchmann P, Sabri O, Schober O, Schicha H, Kluge R. FDG-PET in Hodgkin lymphoma. *Nuklearmedizin* 2008; 47: 235-238.

Reiners C, Dietlein M, Luster M. Struma maligna – Schilddrüsenkarzinome. *Dtsch Med Wochenschr* 2008; 133: 2215-2228.

Schicha H, Eschner W, Fischer T, Dietlein M, Schmidt M, Schomäcker K. Derzeitiger Stand und Entwicklungstendenzen in der Nuklearmedizin. *Nova Acta Leopoldina* 2008; 96(355): 133 – 141.

Kobe C, Kracht LW, Timmermann L, Bachmann J, Schmidt M. Perrault syndrome with progressive nervous system involvement. *Clin Nucl Med* 2008; 33: 922-924.

Schmidt M, Huff W, Dietlein M, Kobe C, Schicha H. Interactions between brain, psyche and thyroid. *Nuklearmedizin* 2008; 47: 225-234.

Sudbrock F, Boldt F, Kobe C, Eschner W, Schicha H. Radiation exposure in the environment of patients after application of radiopharmaceuticals. Part 1: Diagnostic procedures. *Nuklearmedizin* 2008; 47: 267-274.

Fischer T, Schomäcker K, Schicha H. Diethylstilbestrol (DES) labeled with Auger emitters: Potential radiopharmaceutical for therapy of estrogen receptor-positive tumors and their metastases? *Int J Radiat Biol* 2008; 84: 1112-22.

## Publikationen 2009

Schmidt M, Bollschweiler E, Dietlein M, Mönig SP, Kobe C, Vallboehmer D, Eschner W, Hölscher A, Schicha H. Mean and maximum standardized uptake values in [<sup>18</sup>F] FDG-PET for assessment of histopathological response in oesophageal squamous cell carcinoma or adenocarcinoma after radiochemotherapy. *Eur J Nucl Med Mol Imaging* 2009; 36: 735-740.

Markova J, Kobe C, Skopalova M, Klaskova K, Dedeckova K, Plütschow A, Eich HT, Dietlein M, Engert A, Kozak T. FDG-PET for assessment of early treatment response after 4 cycles of chemotherapy in patients with advanced-stage Hodgkin lymphoma has a high negative predictive value. *Ann Oncol* 2009; 20: 1270-1274.

Verburg FA, Dietlein M, Lassmann M, Luster M, Reiners C. Why radioiodine remnant ablation is right for most patients with differentiated thyroid carcinoma. *Eur J Nucl Med Mol Imaging* 2009; 36: 343-346.

Sudbrock F, Boldt F, Kobe C, Hammes J, Eschner W, Schicha H. Radiation exposure in the environment of patients after application of radiopharmaceuticals. Part 2: Therapeutic procedures. *Nuklearmedizin* 2009; 48: 17-25.

Furth C, Steffen IG, Amthauer H, Ruf J, Misch D, Schönberger S, Kobe C, Denecke T, Stöver B, Hautzel H, Henze G, Hundsdorfer P. Early and late therapy response assessment with FDG-PET in pediatric Hodgkin lymphoma: an analysis of a prospective multicenter trial. *J Clin Oncol* 2009; 27(26): 4385 - 4391.

Nogová L, Boellaard R, Kobe C, Hoetjes N, Zander T, Gross SH, Dimitrijevic S, Pellas T, Eschner W, Schmidt K, Bangard C, Hayes W, Thomas RK, Dietlein M, Giaccone G, Hoekstra OS, Lammertsma AA, Wolf J. Downregulation of 18F-FDG uptake in PET as an early pharmacodynamic effect in treatment of non-small cell lung cancer with the mTOR inhibitor everolimus. *J Nucl Med* 2009; 50(11): 1815 - 1819.

Bachmann J, Kobe C, Bor S, Rahlff I, Dietlein M, Schicha H, Schmidt M. Radioiodine therapy for thyroid volume reduction of large goitres. *Nucl Med Commun* 2009; 30: 466-471.

Vallböhmer D, Hölscher AH, Dietlein M, Bollschweiler E, Baldus S, Mönig S, Metzger R, Schicha H, Schmidt M. [<sup>18</sup>F]-fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer. *Ann Surgery* 2009; 250: 888-894.

Theissen P, Schmidt M, Ivanova T, Dietlein M, Schicha H. MIBI scintigraphy in hypofunctioning thyroid nodules. Can it predict the dignity of the lesion? *Nuklearmedizin* 2009; 48: 144-152.

Schicha H, Hellmich M, Lehmacher W, Eschner W, Schmidt M, Kobe C, Schober O, Dietlein M. Should all patients with thyroid nodules  $\geq 1$  cm undergo fine-needle aspiration biopsy? *Nuklearmedizin* 2009; 48: 79-83.

Albus C, Theissen P, Hellmich M, Griebenow R, Wilhelm B, Aslim D, Schicha H, Köhle K. Long-term effects of a multimodal behavioral intervention on myocardial perfusion – a randomized controlled trial. *Int J Behav Med* 2009; 16(3): 219-226.

Klehr M, Koehl U, Mühlenhoff M, Tawadros S, Fischer T, Schomäcker K, Heuckmann JM, Bochennek K, Jensen M. The novel chimeric anti-NCAM (Neural Cell Adhesion Molecule) antibody ch.MK1 displays antitumor activity in SCID mice but does not activate complement-dependent cytotoxicity (CDC). *J Immunother* 2009; 32: 442-451.

## Publikationen 2010

Eschner W, Schmidt M, Dietlein M, Schicha H. PROLARA: prognosis-based lifetime attributable risk approximation for cancer from diagnostic radiation exposure. *Eur J Nucl Med Mol Imaging* 2010; 37(1): 131 - 135.

Düren C, Dietlein M, Luster M, Plenzig F, Steinke R, Grimm J, Groth P, Reiners C. The use of thyrogen in the treatment of differentiated thyroid carcinoma: an intraindividual comparison of clinical effects and economic aspects. *Exp Clin Endocrinol Diabetes* 2010; 118: 513-519.

Kobe C, Eschner W, Wild M, Rahlff I, Sudbrock F, Schmidt M, Dietlein M, Schicha H. Radioiodine therapy of benign thyroid disorders: what are the effective thyroidal half-life and uptake of  $^{131}\text{I}$ ? *Nucl Med Commun* 2010; 31: 201-205.

Kotzerke J, Dietlein M, Grünwald F, Bockisch A. Vorbehalte der DGN zur Nutzenbewertung der PET durch das IQWiG. *Nuklearmedizin* 2010; 49(1): 6 - 12.

Kobe C, Dietlein M, Fuchs M. Interim positron emission tomography scan in Hodgkin lymphoma: definitions, interpretation rules, and clinical validation [letter]. *Leukemia Lymphoma* 2010; 51(3): 552 - 553.

Breustedt B, Eschner W. Monte Carlo calibration of whole-body counters with NaI(Tl) detectors in Stretcher geometry. *Radiat Prot Dosimetry* 2010; 139(4): 510 – 518.

Dietlein M, Börner SM, Fischer T, Hansen H, Schnell R, Zimmermanns B, Tawadros S, Eschner W, Engert A, Staak JO, Pogge von Strandmann E, Kobe C, Schicha H, Schomäcker K. Development of an iodine-131-labeled murine anti-CD30 monoclonal antibody ( $^{131}\text{I}$ -Ki-4): in vitro studies with L540 Hodgkin cell lines, animal studies and a feasibility study for radioimmunotherapy in patients with refractory Hodgkin's lymphoma. *Nuklearmedizin* 2010; 49(3): 97 - 105.

Vallboehmer D, Hoelscher AH, Schneider PM, Schmidt M, Dietlein M, Bollschweiler E, Baldus S, Alakus H, Brabender J, Metzger R, Moenig SP. [ $^{18}\text{F}$ ]-fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemotherapy in gastric cancer. *J Surg Oncol* 2010; 102: 135-150

Sudbrock F, Schmidt M, Simon T, Eschner W, Berthold F, Schicha H. Dosimetry for  $^{131}\text{I}$ -MIBG therapies in metastatic neuroblastoma, pheochromocytoma and paraganglioma. *Eur J Nucl Med Mol Imaging* 2010; 37: 1279 – 1290.

Alakus H, Batur M, Schmidt M, Drebber U, Baldus SE, Vallböhmer D, Prenzel KL, Metzger R, Bollschweiler E, Hölscher AH, Mönig SP. Variable <sup>18</sup>F-fluorordeoxyglucose uptake in gastric cancer is associated with different levels of GLUT-1 expression. Nucl Med Commun 2010; 31: 532 – 538.

Riemann B, Krämer JA, Schmid KW, Dralle H, Dietlein M, Schicha H, Sauerland C, Frankewitsch T, Schober O. Risk stratification of patients with locally aggressive differentiated thyroid cancer: results of the MSDS trial. Nuklearmedizin 2010; 49: 79 - 84.

Krämer JA, Schmid KW, Dralle H, Dietlein M, Schicha H, Lerch H, Gerss J, Frankewitsch T, Schober O, Riemann B. Primary tumour size is a prognostic parameter in patients suffering from differentiated thyroid carcinoma with extrathyroidal growth: results of the MDS trial. Eur J Endocrinol 2010; 163(4): 637 – 644.

Gassanov G, Dietlein M, Caglayan E, Erdmann E, Er F. Amiodaron-induzierte Schilddrüsenfunktionsstörungen. Dtsch Med Wochenschr. 2010; 135: 807 – 811.

Dietlein M, Eich HT, Fuchs M, Borchmann P, Engert A, Kobe C. PET beim Hodgkin-Lymphom – Verbessert die Positronenemissionstomographie die Behandlung? Der Onkologe 2010; 16: 18-27.

Dietlein M, Luster M, Reiners C. Nuklearmedizinische Therapie und Nachsorge des differenzierten Schilddrüsenkarzinoms: Status quo. Der Onkologe 2010; 16(7): 678-689.

Stokkel MPM, Handkiewicz Junak D, Lassmann M, Dietlein M, Luster M. EANM procedure guidelines for therapy of benign thyroid disease. Eur J Nucl Med Mol Imaging 2010; 37: 2218 - 2228.

Lorenz R, Dietlein M, Reiners C. Stationäre nuklearmedizinische Therapie in Deutschland– Analyse der strukturierten Qualitätsberichte 2004 bis 2008. Nuklearmedizin 2010; 49: 49 – 57.

Dafotakis M, Schmidt M, Meister IG, Fink GR, Dennin A, Nowak DA. Degenerative anterior biopercular syndrome initially misdiagnosed as a psychogenic disorder. J Neurology 2010; 257: 1576 – 1578.

Vogt H, Schmidt M, Bares R, Brenner W, Grünwald F, Kopp J, Reiners C, Schober O, Schümichen C, Schicha H, Sciuk J, Sudbrock F, Wengenmair H. Procedure guideline for sentinel lymph node diagnosis. [Verfahrensanweisung für die nuklearmedizinische Wächter-Lymphknoten (sentinel lymph node; SLN)- Diagnostik. Nuklearmedizin 2010; 49: 167-172.

Kobe C, Dietlein M, Kriz J, Furth C, Fuchs M, Borchmann P, Engert A, Eich HT. The role of PET in Hodgkin lymphoma and its impact on radiation oncology. *Expert Rev Anticancer Ther* 2010; 10(9): 1419-1428.

Dietlein M, Busemeyer S, Kobe C, Schmidt M, Theissen P, Schicha H. Cost-minimization-analysis for recombinant human TSH versus hypothyroidism in the follow-up care of differentiated thyroid cancer. *Nuklearmedizin* 2010; 49: 216 – 224.

Schmidt M, Bollschweiler E, Hölscher A. F-18-Fluorodeoxyglucose positron emission tomography for the evaluation of neoadjuvant therapy response in esophageal cancer. (Letter) *Ann Surg* 2010; 252: 412-413.

Schmidt M, Baum RP, Simon T, Howman-Giles R. Therapeutic nuclear medicine in pediatric malignancy. *Q J Nucl Med Mol Imaging* 2010; 54: 411-428.

Wilkens H, Lang I, Behr J, Berghaus T, Grohe C, Guth S, Hoepfer MM, Kramm T, Krüger U, Langer F, Schäfers HJ, Schmidt M, Seyfarth HJ, Wahlers T, Worth H, Mayer E. Chronische thromboembolische pulmonale Hypertonie. Empfehlungen der Kölner Konsensus-Konferenz 2010. *Dtsch Med Wochenschr* 2010; 135: S125 – S130.

Nia AM, Gassanov N, Schmidt M, Kuhn-Régnier F, Erdmann E, Er F. Rare cause for sudden right heart failure. *The Scientific World Journal* 2010; 10: 1996 – 1998 (DOI 10.1100/tsw.2010.190).

Dietlein M, Luster M, Reiners C. Differenziertes Schilddrüsenkarzinom: risikoadaptierte Behandlung und Nachsorge – Update 2010. *Thieme-Refresher Onkologie* 2010; 3(1): R1 – R24.

Dietlein M, Kobe C, Luster M. Differenziertes Schilddrüsenkarzinom: Fortschritte bei der Radioiod-Ablation. *Der Nuklearmediziner* 2010; 33(4):203 – 213.

Schmidt M, Schicha H. MIBI-SPECT bei kalten Knoten zur Schilddrüsenkarzinomdetektion. *Der Nuklearmediziner* 2010; 33(4): 214 – 221.

Dietlein M, Kobe C, Neumaier B, Ullrich R. Nichtkleinzelliges Bronchialkarzinom: Molekulare Bildgebung mittels PET und translationale Forschung. *onkopipeline* 2010; 3(2): 99 - 105.

Kobe C, Dietlein M. Die Positronenemissionstomografie in den Hodgkin-Lymphom-Studien der GHSG. *Krebsmedizin* 2010; 19(3): 117 - 122.

Zimmermanns B, Fischer T, Schomäcker K. Qualitätskontrolle von Radiopharmaka – Gesetzliche Grundlagen (1). MTA Dialog 2010; 11(2): 112 – 114.

Zimmermanns B, Fischer T, Schomäcker K. Qualitätskontrolle von Radiopharmaka – Qualitätskriterien (2). MTA Dialog 2010; 11(3): 188 – 191.

Zimmermanns B, Fischer T, Schomäcker K. Qualitätskontrolle von Radiopharmaka – Kontrolle der radiochemischen Reinheit (3). MTA Dialog 2010; 11(4): 282 – 285.

Luster M, Dietlein M. Therapie gutartiger Schilddrüsenerkrankungen – Wann Medikamente, wann Radioiod, wann Op.? Der Allgemeinarzt 2010, Heft 13: 3-10.